Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

Phase 1
16(100.0%)
16Total
Phase 1(16)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT07504523Phase 1Recruiting

Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer

Role: collaborator

NCT07504484Phase 1Completed

Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer

Role: collaborator

NCT07368803Phase 1Recruiting

Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection

Role: collaborator

NCT05307835Phase 1Active Not Recruiting

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Role: collaborator

NCT07123545Phase 1Recruiting

Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma

Role: collaborator

NCT06995105Phase 1Recruiting

Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma

Role: collaborator

NCT06956716Phase 1Recruiting

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Role: collaborator

NCT06888648Phase 1Not Yet Recruiting

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Role: collaborator

NCT06888674Phase 1Not Yet Recruiting

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Role: collaborator

NCT06026774Phase 1Recruiting

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms

Role: collaborator

NCT06019702Phase 1Recruiting

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms

Role: collaborator

NCT06026800Phase 1Recruiting

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms

Role: collaborator

NCT03662815Phase 1Unknown

Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor

Role: collaborator

NCT04810910Phase 1Unknown

Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Role: collaborator

NCT03645148Phase 1Completed

Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer

Role: collaborator

NCT04864379Phase 1Unknown

Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors

Role: collaborator

All 16 trials loaded